Douglas F. Kling - Jan 2, 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Chief Operating Officer
Signature
/s/ Louise Kooij by Power of Attorney from Douglas F. Kling
Stock symbol
NAMS
Transactions as of
Jan 2, 2025
Transactions value $
$0
Form type
4
Date filed
1/6/2025, 05:57 PM
Previous filing
Jan 3, 2024
Next filing
Jan 7, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Option (right to buy) Award $0 +250K $0.00 250K Jan 2, 2025 Ordinary Shares 250K $25.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option will vest on January 2, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.